ASP Isotopes (NASDAQ:ASPI) COO Sells $112,750.00 in Stock

ASP Isotopes Inc. (NASDAQ:ASPI) COO Robert Ainscow sold 25,000 shares of the company’s stock in a transaction on Friday, March 6th. The shares were sold at an average price of $4.51, for a total value of $112,750.00. Following the completion of the sale, the chief operating officer owned 1,512,817 shares in the company, valued at $6,822,804.67. This represents a 1.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Robert Ainscow also recently made the following trade(s):

• On Friday, March 6th, Robert Ainscow sold 8,438 shares of ASP Isotopes stock. The shares were sold at an average price of $5.44, for a total value of $45,902.72.

ASP Isotopes Stock Up 12.9%

Shares of NASDAQ:ASPI opened at $5.06 on Tuesday. The company has a quick ratio of 6.10, a current ratio of 6.14 and a debt-to-equity ratio of 1.04. ASP Isotopes Inc. has a 52-week low of $3.92 and a 52-week high of $14.49. The stock’s fifty day simple moving average is $5.10 and its 200-day simple moving average is $6.83. The company has a market capitalization of $560.85 million, a P/E ratio of -2.36 and a beta of 3.59.

ASP Isotopes (NASDAQ:ASPI) last issued its quarterly earnings data on Friday, April 10th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.70). ASP Isotopes had a negative net margin of 734.14% and a negative return on equity of 307.82%. The company had revenue of $33.32 million during the quarter, compared to analysts’ expectations of $2.03 million. As a group, equities research analysts forecast that ASP Isotopes Inc. will post -0.24 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of ASP Isotopes in a research note on Friday, March 27th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $13.00.

Institutional Investors Weigh In On ASP Isotopes

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd increased its stake in ASP Isotopes by 177.2% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 34,983 shares of the company’s stock worth $187,000 after acquiring an additional 22,361 shares during the last quarter. Pacer Advisors Inc. acquired a new stake in ASP Isotopes during the fourth quarter worth about $2,163,000. Compound Planning Inc. acquired a new stake in ASP Isotopes during the fourth quarter worth about $82,000. Mercer Global Advisors Inc. ADV increased its stake in ASP Isotopes by 21.3% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 25,550 shares of the company’s stock worth $137,000 after acquiring an additional 4,494 shares during the last quarter. Finally, Empowered Funds LLC acquired a new stake in ASP Isotopes during the fourth quarter worth about $720,000. 16.80% of the stock is currently owned by institutional investors and hedge funds.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.